P551: Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn's disease: application and prospective validation.ECCO’23 CopenhagenYear: 2023
Authors: Macedo Silva, V.(1)*;Ferreira, A.I.(1);Lima Capela, T.(1);Arieira, C.(1);Cúrdia Gonçalves, T.(1);Boal Carvalho, P.(1);Dias de Castro, F.(1);Moreira, M.J.(1);Cotter, J.(1);
(1)Hospital da Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal;
P552: Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease PatientsECCO’23 CopenhagenYear: 2023
Authors: Cohen, Y.(1);Fischman, M.(1);Waterman, M.(2);Dolnikov, K.(3);Azzam, Z.S.(3);Ghersin, I.(2)*;
(1)Faculty of Medicine- Hebrew University of Jerusalem, Department of Military Medicine, Jerusalem, Israel;(2)Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel;(3)Rambam Health Care Campus, Department of Internal Medicine "B", Haifa, Israel;
P553: Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indicationsECCO’23 CopenhagenYear: 2023
Authors: Ghosh, S.(1)*;Long, M.(2);Ott, E.(3);Gasink, C.(3);Baker, T.(4);Godwin, B.(3);Miao, Y.(4);Loftus, E.(5);
(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, United States;(3)Janssen, Scientific Affairs, Horsham, United States;(4)Janssen, Research & Development, Spring House, United States;(5)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;
P554: Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trialsECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Higgins, P.D.R.(2);Peyrin-Biroulet, L.(3);Sands, B.E.(4);Lee, S.(5);Moses, R.E.(6);Redondo, I.(7)*;Escobar, R.(8);Morris, N.(9);Kobayashi, T.(10);
(1)Amsterdam University Medical Centers, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands;(2)University of Michigan, Department of Internal Medicine, Michigan, United States;(3)University Hospital of Nancy, Gastroenterology, Nancy, France;(4)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(5)University of Washington Medical Center, Digestive Health Center, Washington, United States;(6)Eli Lilly and Company, Gastroenterology, Indianapolis, United States;(7)Eli Lilly Portugal, Produtos Farmacêuticos Lda., Lisbon, Portugal;(8)Eli Lilly Spain, Immunology, Alcobendas, Spain;(9)Eli Lilly and Company, Statistics, Indianapolis, United States;(10)Kitasato University -Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;
P555: Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseasesECCO’23 CopenhagenYear: 2023
Authors: Grimsdottir, S.(1);Attauabi, M.(1,2)*;Dahl, E.K.(1);Burisch, J.(2,3);Seidelin, J.B.(1);
(1)Copenhagen University Hospital - Herlev and Gentofte- Herlev, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre- Hvidovre, Gastrounit- Medical Division, Hvidovre, Denmark;
P556: Surgery in high-risk paediatric Crohn's Disease treated with up-front anti-TNF agents and long-standing biologic therapyECCO’23 CopenhagenYear: 2023
Authors: Musto, F.(1)*;Distante, M.(2);Dei Rossi, E.(2);Calicchia, A.(3);Veraldi, S.(4);Mondi', F.(2);Tarani, F.(2);D'Arcangelo, G.(2);Aloi, M.(2);
(1)Sapienza University, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Roma, Italy;(2)Sapienza University, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Rome, Italy;(3)Sapienza Univerisy, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Rome, Italy;(4)Sapienza University, Department of Anatomical-Histological-Forensic and Locomotor Apparatus Sciences, Rome, Italy;
P557: Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort studyECCO’23 CopenhagenYear: 2023
Authors: Jenkinson, P.(1)*;Plevris, N.(2);Gros Alcalde, B.(2);Lyons, M.(2);Derikx, L.(2);Constantine-Cooke, N.(3);Arnott, I.(2);Jones, G.(2);Lees, C.(2);
(1)NHS Lothian, Gastroenterology, Rosewell, United Kingdom;(2)Western General Hospital, GI Department, Edinburgh, United Kingdom;(3)University of Edinburgh, Igc, Edinburgh, United Kingdom;
P558: Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Regueiro, M.(1);Siegmund, B.(2)*;Yarur, A.(3);Steinwurz, F.(4);Gecse, K.B.(5);Goetsch, M.(6);Bhattacharjee, A.(7);Wu, J.(8);Green, J.(9);McDonnell, A.(10);Crosby, C.(11);Lazin, K.(12);Ferreira Branquinho, D.(13);Modesto, I.(14);Abreu, M.T.(15);
(1)Cleveland Clinic, Gastroenterology, Cleveland- Ohio, United States;(2)Medizinische Klinik für Gastroenterologie- Infektiologie und Rheumatologie- Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany;(3)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(4)Hospital Israelita Albert Einstein, Gastroenterology, São Paulo, Brazil;(5)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;(6)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(7)Pfizer Healthcare India Pvt. Ltd., Biostatistics, Chennai, India;(8)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(9)Pfizer Inc, Field Medical- Gastroenterology, Collegeville- Pennsylvania, United States;(10)Pfizer Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(11)Pfizer Inc, Translational Medicine, New York- New York, United States;(12)Pfizer AG, Clinical Development, Zurich, Switzerland;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Lisbon, Portugal;(14)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(15)University of Miami Miller School of Medicine, Gastroenterology, Miami- Florida, United States;
P560: Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trialECCO’23 CopenhagenYear: 2023
Authors: Ben-Horin, S.(1);Salomon, N.(1)*;Karampekos, G.(2);Viazis, N.(2);Lahat, A.(1);Ungar, B.(1);Eliakim, R.(1);Kriger-Sharabi, O.(3);Reiss-Mintz, H.(4);Yanai, H.(5);Dotan, I.(6);Zittan, E.(7);Maharshak, N.(8);Hirsch, A.(9);Weitman, M.(10);Mantzaris, G.J.(2);Kopylov, U.(1);
(1)Sheba Medical Center- Tel-Avivi University, Gastroenterology, Ramat Gan, Israel;(2)Evangelismos-Polykliniki- GHA, Gastroenterology, Athens, Greece;(3)Assuta Medical Center, Gastroenterology, Ashdod, Israel;(4)Mayanei HaYeshua Medical Center, Gastroenterology, Bnei Brak, Israel;(5)Rabin Medical Center, Gastroenterology, - Petah Tikva, Israel;(6)Rabin Medical Center, Gastroenterology, Petah Tiqva, Israel;(7)Emek Medical Center, Gastroenterology, Afula, Israel;(8)Tel Aviv Medical Center, Gastroenterology, Tel-Aviv, Israel;(9)Tel-Aviv Medical Center, Gastroenterology, Tel-Aviv, Israel;(10)Bar-Ilan University, Chemistry, Ramat Gan, Israel;
P561: Risk of stoma formation in patients with Crohn's perianal fistulas over a two decades period. A cohort study from a tertiary referral center.ECCO’23 CopenhagenYear: 2023
Authors: Bislenghi, G.(1)*;Baldi, C.(1);Ferrante, M.(2);Sabino, J.(2);Verstockt, B.(2);Wolthuis, A.(1);Vermeire, S.(2);D'Hoore, A.(1);
(1)UZ Leuven, Abdominal Surgery, Leuven, Belgium;(2)UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium;
P562: Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary centerECCO’23 CopenhagenYear: 2023
Authors: Cohen, N.A.(1)*;Choi, D.(1);Garcia, N.(1);Choi, N.(1);Picker, E.(1);Krugliak-Cleveland, N.(1);Cohen, R.(1);Dalal, S.(1);Sakuraba, A.(1);Pekow, J.(1);Rubin, D.(1);
(1)University of Chicago Medicine, IBD Center- Section of Gastroenterology- Hepatology and Nutrition, Chicago, United States;
P563: Monitoring of vedolizumab drug levels in a treat to target strategy for moderate-severe IBD (MOVE-IBD)ECCO’23 CopenhagenYear: 2023
Authors: Logan, H.(1)*;Rimmer, K.(1);Doecke, J.(2);Patrick, D.(1);
(1)Sunshine Coast University Public Hospital, Department of Gastroenterology and Hepatology, Sunshine Coast, Australia;(2)Royal Brisbane and Women's Hospital, CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Australia;
P564: vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease – a meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Yiu, T.H.(1)*;Leong, R.(2);Ko, Y.(2);Pudipeddi, A.(2);
(1)University of Sydney, Faculty of Medicine and Health, Sydney, Australia;(2)Concord Repatriation General Hospital, Gastroenterology and Liver Services, Sydney, Australia;
P565: Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patientsECCO’23 CopenhagenYear: 2023
Authors: Biscanin, A.(1,2)*;Tomašić, V.(1);Babic, F.(1);Ćaćić, P.(1);Ogresta Kordej, D.(1);Hrabar, D.(1,2);Kralj, D.(1);Dorosulić, Z.(1);
(1)Sisters of Charity University Hospital, Department of Gastroenterology, Zagreb, Croatia;(2)University of Zagreb, School of medicine, Zagreb, Croatia;
P566: Colitis due to immunotherapy with anti-PD-1: a case seriesECCO’23 CopenhagenYear: 2023
Authors: De Ruvo, M.(1)*;Barberio, B.(1);Zingone, F.(1);Bonanno, L.(2);Dal Maso, A.(2);Stefano, F.(2);Chiarion Sileni, V.(3);Savarino, E.V.(1);
(1)University of Padua- Division of Gastroenterology, Department Of Surgery- Oncology And Gastroenterology, Padua, Italy;(2)Veneto Institute of Oncology IOV – IRCCS, Oncology 2 Unit- Department of Medical Oncology, Padua, Italy;(3)Veneto Institute of Oncology IOV – IRCCS, Melanoma Unit Department of Oncology, Padua, Italy;
P567: How can we predict the development of antibodies to infliximab in Crohn's disease?ECCO’23 CopenhagenYear: 2023
Authors: Ferreira, A.I.(1)*;Lima Capela, T.(1);Macedo Silva, V.(1);Xavier, S.(1);Arieira, C.(1);Cúrdia Gonçalves, T.(1);Dias de Castro, F.(1);Moreira, M.J.(1);Cotter, J.(1);
(1)Hospital da Senhora da Oliveira - Guimarães, Gastroenterology Department, Guimarães, Portugal;
P568: Patients with ulcerative colitis after pouch surgery are at risk for low spinal bone mineral density: a cross sectional studyECCO’23 CopenhagenYear: 2023
Authors: Pfeffer-Gik, T.(1)*;Godny , L.(1);Ollech, J.(1);Wasserberg, N.(2);White , I.(2);Barkan , R.(1);Cohen , S.(1);Avni-Biron, I.(1);Banai, H.(1);Snir, Y.(1);Yanai, H.(1);Yackobovich Gavan, M.(3,4);Shimon , I.(5);Tsvetov, G.(5);Broitman, Y.(1);Dotan, I.(1);
(1)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Division of Gastroenterology, Petah Tikva, Israel;(2)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Colorectal Unit- Division of Surgery, Petah Tikva, Israel;(3)Schneider Childrens Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes- National Center for Childhood Diabetes, Petah Tikva, Israel;(4)Tel Aviv University, Dept. of Epidemiology and Preventive Medicine- School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;(5)Rabin medical center- Beilinson campus- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Institute of endocrinology- diabetes and metabolism, Petah Tikva, Israel;
P570: Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data from TOFA-UC, a SN-IBD StudyECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;D'Antonio, E.(2);Fries, W.(3);Viola, A.(3);Ksissa, O.(3);Cappello, M.(4);Muscarella, S.(4);Belluardo, N.(5);Giangreco, E.(5);Mocciaro, F.(6);Di Mitri, R.(6);Ferracane, C.(7);Vitello, A.(8);Grova, M.(1);Renna, S.(1);Casà, A.(1);Ventimiglia, M.(9);Orlando, A.(1);
(1)“Villa Sofia-Cervello” Hospital, IBD Unit, Palermo, Italy;(2)Scuola Medica Salernitana- University of Salerno, Department of Medicine- Surgery and Dentistry, Salerno, Italy;(3)"G. Martino” Hospital, IBD Unit, Messina, Italy;(4)University of Palermo, Gastroenterology & Hepatology Section- PROMISE, Palermo, Italy;(5)“Guzzardi” Hospital, Gastroenterology Unit, Vittoria, Italy;(6)“ARNAS Civico - Di Cristina – Benfratelli” Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy;(7)“Vittorio Emanuele” Hospital, Gastroenterology Unit, Catania, Italy;(8)“S. Elia- Raimondi” Hospital, Gastroenterology and Endoscopy Unit, Caltanissetta, Italy;(9)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Rome, Italy;Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
